Physician profile
James C Althoff
NPI 1306952098
$4,308.52
in general payments reported to CMS, 2019-2025
35 companies · $776 in 2025
The $776 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $808 · 2020: $179 · 2021: $510 · 2022: $742 · 2023: $766 · 2024: $528 · 2025: $776.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,070.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,069.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,000.45 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $660.03 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $376.83 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Glaxosmithkline, LLC. | $244.12 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Novo Nordisk INC | $231.07 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $219.73 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $188.55 | 2022-2025 | Xifaxan |
| Abbvie INC. | $139.65 | 2019-2025 | Ubrelvy, Qulipta |
| Amarin Pharma, INC. | $127.86 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $124.67 | 2019-2024 | |
| Astellas Pharma US INC | $113.06 | 2019-2024 | Veozah, Myrbetriq |
| Exact Sciences Corporation | $107.30 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Janssen Pharmaceuticals, INC | $91.17 | 2019-2021 | |
| Dexcom, INC. | $88.86 | 2021-2023 | Dexcom G6 Transmitter |
| E.R. Squibb & Sons, L.L.C. | $69.77 | 2019-2023 | Eliquis |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $60.36 | 2019-2020 | |
| Amgen INC. | $59.00 | 2019-2025 | Repatha, Otezla |
| Sanofi-Aventis U.S. LLC | $57.01 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $41.59 | 2022-2023 | |
| Phathom Pharmaceuticals, INC. | $36.12 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $34.85 | 2021-2022 | |
| Axsome Therapeutics, INC. | $29.19 | 2025 | Auvelity |
| Esperion Therapeutics, INC. | $20.73 | 2021 | |
| Ironshore Pharmaceuticals INC. | $20.14 | 2019 | |
| Orapharma, A Division of Bausch Health US, LLC | $19.68 | 2024 | Arestin |
| Eisai INC. | $17.88 | 2025 | |
| Nestle Healthcare Nutrition INC. | $17.85 | 2022 | |
| Agile Therapeutics, INC. | $17.10 | 2022 | |
| Assertio Therapeutics, INC. | $15.76 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $15.56 | 2019 | |
| Sanofi Pasteur INC. | $13.63 | 2019 | |
| Abbott Laboratories | $13.03 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $12.32 | 2021 | |
| Sunovion Pharmaceuticals INC. | $11.85 | 2022 | |
| Shire North American Group INC | $11.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Althoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.